月経過多症の世界市場レポート 2025年

月経過多症市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.2％で、280億米ドルに成長します。予測期間に予測される成長は、高齢者人口の拡大、子宮内避妊器具の使用増加、技術の進歩、低侵襲処置への嗜好の高まり、予防ヘルスケアへの注目の高まりなどの要因によってもたらされます。この期間に予想される主な動向には、治療選択肢の発展、持続可能で環境に優しい治療への注目、さらなる技術の進歩、ホルモン投与方法の改善、革新的な治療法の開発などがあります。

ホルモンバランスの乱れの有病率の増加は、今後の月経過多症市場の成長を促進すると予想されます。ホルモンバランスの乱れは、体内のホルモンが過剰または不足することで起こり、体重の変動、気分の変化、疲労、生殖に関する問題など、さまざまな健康問題を引き起こします。現代的なライフスタイル、環境の影響、病状などの要因が、これらの不均衡の原因となっています。食生活の乱れ、ストレスレベルの高さ、運動不足などは、ホルモンの産生と調節を乱す可能性があります。ホルモンバランスの乱れは、月経周期の正常な調節を妨げ、子宮環境に影響を与えることで、月経出血症を誘発する可能性があります。例えば、2025年1月、世界保健機関（WHO）は、多嚢胞性卵巣症候群を重大な公衆衛生上の懸念として取り上げ、毎年生殖年齢の女性の6～13％に影響を及ぼしています。その結果、ホルモンバランスの乱れの発生が増加し、月経過多症市場の成長を牽引しています。

月経過多症市場の主要企業は、効果的かつ長期的な治療オプションを提供するため、ホルモン性子宮内避妊器具（IUD）のような革新的なソリューションの開発に注力しています。ホルモン性IUDは、子宮内に装着する小型のT字型器具で、黄体ホルモンを放出し、子宮頸管粘液を濃くし、子宮内膜を薄くし、排卵を抑制することで妊娠を予防します。例えば、2022年10月、ドイツの製薬会社バイエル社は、避妊および特発性月経過多症の治療に使用されるホルモン性IUD「ミレーナ」の欧州における規制当局の承認を取得しました。このデバイスはレボノルゲストレルを持続的に放出し、子宮内膜を薄くして経血量を減らすのに役立ち、毎日の投薬や手術を必要とせずに月経多量出血を管理する実用的で長期的な解決策を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の月経過多症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の月経過多症市場：成長率分析
• 世界の月経過多症市場の実績：規模と成長、2019年～2024年
• 世界の月経過多症市場の予測：規模と成長、2024年～2029年、2034年
• 世界の月経過多症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の月経過多症市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ホルモン剤
• 非ホルモン剤
• 世界の月経過多症市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 膣
• 経皮
• 子宮内
• その他の投与経路
• 世界の月経過多症市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界の月経過多症市場、ホルモン剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 複合経口避妊薬（COC）
• プロゲスチン
• ゴナドトロピン放出ホルモン（GnRH）アゴニスト
• レボノルゲストレル放出子宮内システム（LNG-IUS）
• ダナゾール
• 選択的エストロゲン受容体モジュレーター（SERM）
• 世界の月経過多症市場、非ホルモン剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 非ステロイド性抗炎症薬（NSAID）
• トラネキサム酸
• 抗線溶薬
• 鉄サプリメント
• ハーブと自然療法

第7章 地域別・国別分析

• 世界の月経過多症市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の月経過多症市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 月経過多症市場：競合情勢
• 月経過多症市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer HealthCare Pharmaceuticals Inc.（a division of Bayer AG）Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Johns Hopkins Health System Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Aegea Medical Inc.
• Emory Healthcare Inc.
• Hologic Inc.
• Dr. Reddy's Laboratories Ltd.
• Meril Life Sciences Pvt. Ltd.
• ASKA Pharmaceutical Holdings Co. Ltd.
• Ferring Pharmaceuticals Group
• Minerva Infra Tech Private Limited
• Roivant Sciences Ltd.
• Xanodyne Pharmaceuticals Inc.
• Pregna International Ltd.
• HLL Lifecare Limited
• Actiza Pharmaceutical Pvt. Ltd.
• Wellona Pharma
• OCON Healthcare Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 月経過多症市場2029年：新たな機会を提供する国
• 月経過多症市場2029年：新たな機会を提供するセグメント
• 月経過多症市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Menorrhagia, also known as menorrhalgia, refers to excessively heavy or prolonged menstrual bleeding. It is characterized by menstrual cycles lasting longer than seven days or involving blood loss greater than 80 milliliters. This condition can result in fatigue, anemia, and discomfort. Menorrhagia may be caused by factors such as hormonal imbalances, uterine fibroids, polyps, or other underlying health issues.

The primary therapeutic options for menorrhagia are hormonal and non-hormonal agents. Hormonal treatments help manage menorrhagia by regulating hormones to reduce uterine contractions, control the growth of the endometrium, and alleviate both pain and bleeding. These medications can be administered through various methods, including oral, vaginal, transdermal, intrauterine, and other routes. They are available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The menorrhalgia market research report is one of a series of new reports from The Business Research Company that provides menorrhalgia market statistics, including the menorrhalgia industry global market size, regional shares, competitors with the menorrhalgia market share, detailed menorrhalgia market segments, market trends, and opportunities, and any further data you may need to thrive in the menorrhalgia industry. This menorrhalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menorrhalgia market size has grown strongly in recent years. It will grow from $20.61 billion in 2024 to $21.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historical period can be attributed to factors such as the rising incidence of hormonal imbalances, increased awareness about menorrhalgia, a higher prevalence of gynecological disorders, the growing incidence of endometrial cancer, and better availability of over-the-counter medications.

The menorrhalgia market size is expected to see strong growth in the next few years. It will grow to $28.00 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected for the forecast period is driven by factors such as the expanding geriatric population, an increase in the use of intrauterine devices, technological advancements, a growing preference for minimally invasive procedures, and a rising focus on preventive healthcare. Key trends expected during this period include advancements in treatment options, a focus on sustainable and eco-friendly therapies, further technological progress, improvements in hormone delivery methods, and the development of innovative treatment modalities.

The increasing prevalence of hormonal imbalances is expected to drive the growth of the menorrhagia market in the future. Hormonal imbalances occur when there is an excess or deficiency of hormones in the body, leading to various health issues such as weight fluctuations, mood changes, fatigue, and reproductive problems. Factors such as modern lifestyles, environmental influences, and medical conditions contribute to these imbalances. Poor diet, high stress levels, and lack of physical activity can disrupt hormone production and regulation. Hormonal imbalances can trigger menorrhagia (heavy menstrual bleeding) by interfering with the normal regulation of the menstrual cycle and impacting the uterine environment. For instance, in January 2025, the World Health Organization highlighted polycystic ovary syndrome as a significant public health concern, affecting 6-13% of women of reproductive age annually. Consequently, the increasing occurrence of hormonal imbalances is driving market growth for menorrhagia.

Leading companies in the menorrhagia market are focusing on the development of innovative solutions, such as hormonal intrauterine devices (IUDs), to provide effective and long-term treatment options. A hormonal IUD is a small, T-shaped device placed inside the uterus that releases progestin to prevent pregnancy by thickening cervical mucus, thinning the uterine lining, and inhibiting ovulation. For example, in October 2022, Bayer AG, a German pharmaceutical company, received regulatory approval in Europe for Mirena, a hormonal IUD used for contraception and the treatment of idiopathic menorrhagia. This device continuously releases levonorgestrel, helping to reduce menstrual blood loss by thinning the uterine lining and reducing menstrual flow, offering a practical, long-term solution for managing heavy menstrual bleeding without the need for daily medication or surgery.

In January 2025, Hologic Inc., a US-based health technology company, acquired Gynesonics Inc. for an undisclosed sum. This acquisition allows Hologic to expand its portfolio of minimally invasive solutions for treating uterine fibroids and heavy menstrual bleeding, enhancing healthcare options for women. Gynesonics Inc. is a US-based medical device company specializing in systems for treating menorrhagia.

Major players in the menorrhalgia market are AbbVie Inc., Bayer HealthCare Pharmaceuticals Inc. (a division of Bayer AG), Baxter International Inc., Boston Scientific Corporation, Johns Hopkins Health System Corporation, Aegea Medical Inc., Emory Healthcare Inc., Hologic Inc., Dr. Reddy's Laboratories Ltd., Meril Life Sciences Pvt. Ltd., ASKA Pharmaceutical Holdings Co. Ltd., Ferring Pharmaceuticals Group, Minerva Infra Tech Private Limited, Roivant Sciences Ltd., Xanodyne Pharmaceuticals Inc., Pregna International Ltd., HLL Lifecare Limited, Actiza Pharmaceutical Pvt. Ltd., Wellona Pharma, OCON Healthcare Ltd.

North America was the largest region in the menorrhalgia market in 2024. The regions covered in menorrhalgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the menorrhalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The menorrhalgia market consists of revenues earned by entities by providing services such as medical consultation, diagnostic testing, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The menorrhagia market also consists of sales of products including medications, medical devices, and supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Menorrhalgia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on menorrhalgia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for menorrhalgia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The menorrhalgia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Hormonal Agents; Non-Hormonal Agents
• 2) By Route Of Administration: Oral; Vaginal; Transdermal; Intrauterine; Other Route Of Administrations
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Hormonal Agents: Combined Oral Contraceptives (COCs); Progestins; Gonadotropin-Releasing Hormone (GnRH) Agonists; Levonorgestrel-Releasing Intrauterine Systems (LNG-IUS); Danazol; Selective Estrogen Receptor Modulators (SERMs)
• 2) By Non-Hormonal Agents: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Tranexamic Acid; Antifibrinolytics; Iron Supplements; Herbal And Natural Remedies
• Companies Mentioned: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc. (a division of Bayer AG); Baxter International Inc.; Boston Scientific Corporation; Johns Hopkins Health System Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Menorrhalgia Market Characteristics

3. Menorrhalgia Market Trends And Strategies

4. Menorrhalgia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Menorrhalgia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Menorrhalgia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Menorrhalgia Market Growth Rate Analysis
• 5.4. Global Menorrhalgia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Menorrhalgia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Menorrhalgia Total Addressable Market (TAM)

6. Menorrhalgia Market Segmentation

• 6.1. Global Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Agents
• Non-Hormonal Agents
• 6.2. Global Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Vaginal
• Transdermal
• Intrauterine
• Other Route Of Administrations
• 6.3. Global Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.4. Global Menorrhalgia Market, Sub-Segmentation Of Hormonal Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combined Oral Contraceptives (COCs)
• Progestins
• Gonadotropin-Releasing Hormone (GnRH) Agonists
• Levonorgestrel-Releasing Intrauterine Systems (LNG-IUS)
• Danazol
• Selective Estrogen Receptor Modulators (SERMs)
• 6.5. Global Menorrhalgia Market, Sub-Segmentation Of Non-Hormonal Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Tranexamic Acid
• Antifibrinolytics
• Iron Supplements
• Herbal And Natural Remedies

7. Menorrhalgia Market Regional And Country Analysis

• 7.1. Global Menorrhalgia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Menorrhalgia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Menorrhalgia Market

• 8.1. Asia-Pacific Menorrhalgia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Menorrhalgia Market

• 9.1. China Menorrhalgia Market Overview
• 9.2. China Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Menorrhalgia Market

• 10.1. India Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Menorrhalgia Market

• 11.1. Japan Menorrhalgia Market Overview
• 11.2. Japan Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Menorrhalgia Market

• 12.1. Australia Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Menorrhalgia Market

• 13.1. Indonesia Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Menorrhalgia Market

• 14.1. South Korea Menorrhalgia Market Overview
• 14.2. South Korea Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Menorrhalgia Market

• 15.1. Western Europe Menorrhalgia Market Overview
• 15.2. Western Europe Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Menorrhalgia Market

• 16.1. UK Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Menorrhalgia Market

• 17.1. Germany Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Menorrhalgia Market

• 18.1. France Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Menorrhalgia Market

• 19.1. Italy Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Menorrhalgia Market

• 20.1. Spain Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Menorrhalgia Market

• 21.1. Eastern Europe Menorrhalgia Market Overview
• 21.2. Eastern Europe Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Menorrhalgia Market

• 22.1. Russia Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Menorrhalgia Market

• 23.1. North America Menorrhalgia Market Overview
• 23.2. North America Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Menorrhalgia Market

• 24.1. USA Menorrhalgia Market Overview
• 24.2. USA Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Menorrhalgia Market

• 25.1. Canada Menorrhalgia Market Overview
• 25.2. Canada Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Menorrhalgia Market

• 26.1. South America Menorrhalgia Market Overview
• 26.2. South America Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Menorrhalgia Market

• 27.1. Brazil Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Menorrhalgia Market

• 28.1. Middle East Menorrhalgia Market Overview
• 28.2. Middle East Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Menorrhalgia Market

• 29.1. Africa Menorrhalgia Market Overview
• 29.2. Africa Menorrhalgia Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Menorrhalgia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Menorrhalgia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Menorrhalgia Market Competitive Landscape And Company Profiles

• 30.1. Menorrhalgia Market Competitive Landscape
• 30.2. Menorrhalgia Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer HealthCare Pharmaceuticals Inc. (a division of Bayer AG) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Johns Hopkins Health System Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Menorrhalgia Market Other Major And Innovative Companies

• 31.1. Aegea Medical Inc.
• 31.2. Emory Healthcare Inc.
• 31.3. Hologic Inc.
• 31.4. Dr. Reddy's Laboratories Ltd.
• 31.5. Meril Life Sciences Pvt. Ltd.
• 31.6. ASKA Pharmaceutical Holdings Co. Ltd.
• 31.7. Ferring Pharmaceuticals Group
• 31.8. Minerva Infra Tech Private Limited
• 31.9. Roivant Sciences Ltd.
• 31.10. Xanodyne Pharmaceuticals Inc.
• 31.11. Pregna International Ltd.
• 31.12. HLL Lifecare Limited
• 31.13. Actiza Pharmaceutical Pvt. Ltd.
• 31.14. Wellona Pharma
• 31.15. OCON Healthcare Ltd.

32. Global Menorrhalgia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Menorrhalgia Market

34. Recent Developments In The Menorrhalgia Market

35. Menorrhalgia Market High Potential Countries, Segments and Strategies

• 35.1 Menorrhalgia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Menorrhalgia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Menorrhalgia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer